Please login to the form below

Not currently logged in
Email:
Password:

Dextroamphetamine

This page shows the latest Dextroamphetamine news and features for those working in and with pharma, biotech and healthcare.

Shire weathers generic Adderall XR challenge

Shire weathers generic Adderall XR challenge

dextroamphetamine). Authorised generics of Adderall XR sold by Teva and Impax, for which Shire receives a percentage of sales, have been available since 2009, but in June 2012, Actavis launched its

Latest news

  • FDA issues counterfeit Adderall warning

    Legitimate versions of Adderall should contain dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate.

  • Shire's once-daily ADHD drug Venvanse accepted for European review

    In addition to Venvanse, Shire's ADHD portfolio includes Intuniv (guanfacine), approved in the US 2009, and Adderall XR (dextroamphetamine and amphetamine), which has been licensed in the country since 2001.

  • Shire's Q3 net profit doubles

    Products that performed particularly well in the quarter included ADHD treatments Vyvanse (lisdexamfetamine) and Adderall XR (amphetamine, dextroamphetamine mixed salts).

  • Shire ADHD scholarship programme

    use as adjunctive therapy to stimulants; the extended-release drug Vyvanse (lisdexamfetamine dimesylate), which was approved in the US in 2007; and Adderall XR (dextroamphetamine and amphetamine), which was approved in

  • New use cleared for Shire ADHD drug

    The company's ADHD portfolio also includes the extended-release drug VyVanse (lisdexamfetamine dimesylate), which was approved in the US in 2007, and Adderall XR (dextroamphetamine and amphetamine), which was approved

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics